One of the major Italian biotech companies, operating inside the San Raffaele Biomedical Science Park with FDA approved facilities for GMP and GLP procedures, focused on the identification and development of molecular medicine-based therapies for the treatment of cancer and AIDS.

MolMed has five promising products in its development pipeline, three of which are in phase I/II clinical trials: two gene therapy products against cancer and AIDS, a cancer therapeutic vaccine, and two modified cytokines specifically targeting tumor blood vessels.